This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 3 of 4 for:    SB5 samsung'
Previous Study | Return to List | Next Study

A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Samsung Bioepis Co., Ltd.
ClinicalTrials.gov Identifier:
NCT02167139
First received: June 16, 2014
Last updated: November 22, 2016
Last verified: November 2016
History of Changes
Results First Received: November 22, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Rheumatoid Arthritis
Interventions: Drug: Humira (adalimumab)
Drug: SB5 (proposed biosimilar to adalimumab)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
SB5 (Proposed Biosimilar to Adalimumab) SB5 40 mg every other week via subcutaneous injection SB5 (proposed biosimilar to adalimumab)
Humira (Adalimumab) Humira 40 mg every other week via subcutaneous injection to Week 24, then randomised again in a 1:1 ratio to either continue on Humira® 40 mg (Humira®/Humira®) or be transitioned to SB5 40 mg (Humira®/SB5) every other week up to Week 50.
Humira (Adalimumab), Switch to SB5 From Week 24, SB5 40 mg (Humira®/SB5) every other week up to Week 50.
Humira (Adalimumab), Continue as Humira From Week 24, Humira® 40 mg (Humira®/Humira®) every other week up to Week 50.

Participant Flow for 2 periods

 Period 1:   Randomised, Double-blind
    SB5 (Proposed Biosimilar to Adalimumab)   Humira (Adalimumab)   Humira (Adalimumab), Switch to SB5   Humira (Adalimumab), Continue as Humira
STARTED   271   273   0   0 
COMPLETED   254   254   0   0 
NOT COMPLETED   17   19   0   0 
Withdrawal by Subject                11                8                0                0 
Adverse Event                2                9                0                0 
Lack of Efficacy                1                2                0                0 
Other                3                0                0                0 

Period 2:   Transition-extension
    SB5 (Proposed Biosimilar to Adalimumab)   Humira (Adalimumab)   Humira (Adalimumab), Switch to SB5   Humira (Adalimumab), Continue as Humira
STARTED   254   0   125   129 
COMPLETED   248   0   117   124 
NOT COMPLETED   6   0   8   5 
Adverse Event                2                0                2                3 
Withdrawal by Subject                2                0                4                1 
Lack of Efficacy                0                0                1                1 
Other                1                0                1                0 
Lost to Follow-up                1                0                0                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
SB5 (Proposed Biosimilar to Adalimumab)

SB5 40 mg every other week via subcutaneous injection

SB5 (proposed biosimilar to adalimumab)
Humira (Adalimumab)

Humira 40 mg every other week via subcutaneous injection

Humira (adalimumab)

SB5 (proposed biosimilar to adalimumab)
Total Total of all reporting groups

Baseline Measures
   SB5 (Proposed Biosimilar to Adalimumab)   Humira (Adalimumab)   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 271   273   544 
Age 
[Units: Years]
Mean (Standard Deviation) 		 49.8  (12.67)   52.5  (11.91)   51.2  (12.36) 
Gender 
[Units: Participants]
Count of Participants 		     
Female      217  80.1%      224  82.1%      441  81.1% 
Male      54  19.9%      49  17.9%      103  18.9% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   American College of Rheumatology 20% Response Criteria (ACR20)   [ Time Frame: Week 24 ]
  Show Outcome Measure 1

2.  Secondary:   ACR20   [ Time Frame: Week 52 ]
  Show Outcome Measure 2

3.  Secondary:   American College of Rheumatology 50% Response Criteria (ACR50)   [ Time Frame: Week 24, Week 52 ]
  Show Outcome Measure 3

4.  Secondary:   Disease Activity Score Based on a 28 Joint Count (DAS28)   [ Time Frame: Week 24, Week 52 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Director, Clinical Development
Organization: Samsung Bioepis
phone: +82 31 8061 4534
e-mail: dh01.shin@samsung.com



Responsible Party: Samsung Bioepis Co., Ltd.
ClinicalTrials.gov Identifier: NCT02167139     History of Changes
Other Study ID Numbers: SB5-G31-RA
Study First Received: June 16, 2014
Results First Received: November 22, 2016
Last Updated: November 22, 2016